#USA #Burlington #PAQ Therapeutics #PT0253 #KRAS G12D

PAQ Therapeutics to Present Initial Clinical Findings on PT0253

PAQ Therapeutics, a biotechnology firm focused on advancing groundbreaking treatments for KRAS-related cancers, is set to present the preliminary clinical data for its investigational drug PT0253 at the prestigious 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which will take place from November 18 to 20, 2026, in Barcelona, Spain. This symposium is a significant gathering for scientists, clinicians, and industry professionals involved in cancer research, offering a platform for sharing the latest innovations and findings in oncology.

PT0253: A Selective KRAS G12D Degrader

PT0253 is designed specifically to target the KRAS G12D mutation, which is prevalent in certain aggressive forms of cancer. This drug represents a new class of therapies known as selective protein degraders, developed to provide targeted treatment by degrading specific proteins that drive tumor growth. This concept is particularly exciting as KRAS mutations have historically posed a considerable challenge in cancer treatment, with limited options available for patients.

The clinical findings to be presented will shed light on the safety profile and antitumor efficacy of PT0253, particularly in patients who have previously undergone KRAS-targeted therapies. This aspect is crucial as it opens the possibility for patients who have limited alternatives due to resistance to existing treatments.

Presentation Highlights

During the symposium, PAQ Therapeutics will hold a late-breaking oral presentation highlighting the results of its ongoing Phase 1 clinical trial of PT0253, focusing on advanced solid tumors. This presentation, titled “PT0253: A selective KRAS G12D degrader with a differentiated safety profile and therapeutic activity,” is scheduled for November 20, 2026, at 12:36 PM CET, and will provide insights from leading researchers including Leontios Pappas and Alexander I. Spira.

Furthermore, a poster session will discuss the preclinical profile of PT0253, offering a comprehensive overview of its mechanism and potentials in treating KRAS-driven cancers. This dual presentation format underscores PAQ’s commitment to transparency and collaboration within the scientific community.

The Importance of Targeted Therapies

With many cancer treatments lacking specificity and often leading to severe side effects, the development of targeted therapies like PT0253 speaks volumes about the future direction of oncology. The ability to selectively degrade the proteins that contribute to cancer progression could revolutionize how clinicians approach treatment for patients with KRAS mutations.

PAQ Therapeutics’ pipeline also includes PT0511, a pan-KRAS degrader, currently progressing through Phase 1 trials. This underscores the company's dedication to addressing the diverse needs of patients grappling with KRAS-driven tumors.

Patient-Centric Approach

As PAQ Therapeutics prepares for its symposium presentation, the emphasis remains on the ultimate goal of improving patient outcomes. By focusing on precision medicine, the company aims to provide patients with more effective treatment options tailored to their specific genetic profiles, thereby enhancing the efficacy and minimizing the adverse effects often associated with traditional therapies.

Conclusion

The upcoming presentation at the EORTC-NCI-AACR Symposium not only marks a significant milestone for PAQ Therapeutics but also represents a hopeful advancement in the treatment landscape for KRAS-driven cancers. With encouraging findings on PT0253, stakeholders eagerly await the continued development of innovative therapies that could potentially transform the lives of countless patients battling these challenging diseases.